Explore

Trendline Trendline
Ionis Pharmaceuticals to Present New Data on Olezarsen for Severe Hypertriglyceridemia at Major Conferences

Ionis Pharmaceuticals to Present New Data on Olezarsen for Severe Hypertriglyceridemia at Major Conferences

Ionis Pharmaceuticals to Present New Data on Olezarsen for Severe Hypertriglyceridemia at Major Conferences
Trendline Trendline
Cambrian Bio to Present ATX-304 Data at American Diabetes Association Sessions

Cambrian Bio to Present ATX-304 Data at American Diabetes Association Sessions

Cambrian Bio to Present ATX-304 Data at American Diabetes Association Sessions
Trendline Trendline
Cambrian Bio to Present ATX-304 Data at American Diabetes Association Meeting

Cambrian Bio to Present ATX-304 Data at American Diabetes Association Meeting

Cambrian Bio to Present ATX-304 Data at American Diabetes Association Meeting
Rapid Read Rapid Read
MEDIPOST Gains FDA Approval for Phase 3 Study of CARTISTEM in U.S.

MEDIPOST Gains FDA Approval for Phase 3 Study of CARTISTEM in U.S.

MEDIPOST, a biotechnology company specializing in cell therapy, has secured FDA approval to conduct a single pivotal Phase 3 study for its knee osteoarthritis treatment, CARTISTEM, in the U.S. This agreement marks a significant step in MEDIPOST's efforts to bring its treatment to the U.S. and Canadian markets. The company plans to leverage successful Phase 3 data from South Korea and Japan, along with real-world evidence from 550 patients, to support its U.S. clinical development. This strategy aims to expedite the treatment's commercial entry into the U.S. market.
Trendline Trendline
Terremoto Biosciences Receives FDA Fast Track Designation for Breast Cancer Drug TER-2013

Terremoto Biosciences Receives FDA Fast Track Designation for Breast Cancer Drug TER-2013

Terremoto Biosciences Receives FDA Fast Track Designation for Breast Cancer Drug TER-2013
Trendline Trendline
Satsuma Pharmaceuticals to Present Migraine Treatment Findings at Scientific Meeting

Satsuma Pharmaceuticals to Present Migraine Treatment Findings at Scientific Meeting

Satsuma Pharmaceuticals to Present Migraine Treatment Findings at Scientific Meeting
Rapid Read Rapid Read
Lundbeck Presents New Migraine Treatment Data at American Headache Society Meeting

Lundbeck Presents New Migraine Treatment Data at American Headache Society Meeting

Lundbeck US has presented new data on its migraine treatment VYEPTI® (eptinezumab-jjmr) at the American Headache Society's 68th Annual Scientific Meeting in Orlando, Florida. The presentations included findings from several trials, such as INFUSE, DELIVER, SUNSET, and RESOLUTION, which focused on real-world data and phase 3 clinical trial analyses. These studies evaluated patient-reported outcomes on headache hours, cognitive symptoms, and dose escalation. Additionally, new phase 2b data on bocunebart, an investigational drug targeting PACAP for migraine prevention, was shared. The INFUSE study, a 12-month observational study, showed sustained improvement in cognitive symptoms for patients who had previously failed CGRP-targeted therapies. Lundbeck emphasized the importance of considering the broader burden of migraine beyond headache days, highlighting the potential long-term impact of preventive treatments.
Rapid Read Rapid Read
Kelun-Biotech Presents Promising Data for B7-H3 ADC SKB500 at ASCO 2026

Kelun-Biotech Presents Promising Data for B7-H3 ADC SKB500 at ASCO 2026

Kelun-Biotech has presented the first-in-human study results of its novel B7-H3 antibody-drug conjugate (ADC) SKB500 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The study involved 192 patients with advanced solid tumors, including small cell lung cancer (SCLC) and esophageal squamous cell carcinoma (ESCC). SKB500 demonstrated significant antitumor activity, with an objective response rate of 42.7% and a disease control rate of 83.9% among patients treated at 12 mg/kg. The study also highlighted a favorable safety profile, with a lower incidence of severe treatment-related adverse events in the 12 mg/kg group compared to the 16 mg/kg group.
Trendline Trendline
Decoy Therapeutics and hVIVO Collaborate to Advance Antiviral Drug Development

Decoy Therapeutics and hVIVO Collaborate to Advance Antiviral Drug Development

Decoy Therapeutics and hVIVO Collaborate to Advance Antiviral Drug Development
Trendline Trendline
Corsair Pharma Reports Positive Phase 1 Results for TRX-248 Transdermal System in PAH Treatment

Corsair Pharma Reports Positive Phase 1 Results for TRX-248 Transdermal System in PAH Treatment

Corsair Pharma Reports Positive Phase 1 Results for TRX-248 Transdermal System in PAH Treatment
Trendline Trendline
Vertex Pharmaceuticals Secures FDA Acceptance for Povetacicept in IgA Nephropathy

Vertex Pharmaceuticals Secures FDA Acceptance for Povetacicept in IgA Nephropathy

Vertex Pharmaceuticals Secures FDA Acceptance for Povetacicept in IgA Nephropathy
Rapid Read Rapid Read
Servier Presents Promising Phase 1 Data for Emiltatug Ledadotin in Adenoid Cystic Carcinoma

Servier Presents Promising Phase 1 Data for Emiltatug Ledadotin in Adenoid Cystic Carcinoma

Servier has announced encouraging Phase 1 clinical trial results for Emiltatug Ledadotin (Emi-Le), an investigational antibody drug conjugate (ADC) targeting B7-H4, at the ASCO 2026 Annual Meeting. The trial involved 180 patients with advanced or metastatic solid tumors, including 48 with adenoid cystic carcinoma (ACC). Emi-Le demonstrated a favorable safety profile and promising efficacy, with a 35.6% objective response rate and an 82.2% disease control rate among ACC patients. The U.S. FDA has granted Breakthrough Designation to Emi-Le for treating locally advanced, recurrent, or metastatic ACC, highlighting the critical need for targeted therapies in this patient population.